Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Trial details
- Registry ID
- NCT02665065
- Drugs studied
- Conventional Care, HCT, Iomab-B
TrialRedline tracks 2 clinical trials sponsored by Actinium Pharmaceuticals: 1 Phase 3, 1 Phase 2 / 3.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid LeukemiaNCT02665065 | Conventional Care, HCT, Iomab-B | Active not recruiting | 2022-06Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AMLNCT07157514 | 131I-apamistamab, Allogeneic Hematopoietic Stem Cell Transplant (HSCT), Cyclophosphamide, Fludarabine and 1 more | Not yet recruiting | 2029-02Estimated |
Names as written in the registry records.